Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We've been very pleased with the performance of the business |
| And really, we've been benefiting over the last few years from all three of those |
| We anticipate that the strength we're seeing across our solution set and prescription technology solutions will lead to growth at the top end or slightly above the long-term target |
| It is one team executing this enterprise strategy and I'm proud of what we've been able to achieve as a team |
| This solid financial performance is driven by that focus execution against our company priorities as a diversified healthcare services company we are uniquely positioned to improve healthcare in every setting |
| And we remain confident in our ability to continue to deliver sustainable long-term growth |
| McKesson continues to make really meaningful progress in advancing our strategy and our mission |
| And I'd say we're very pleased with the performance and very committed to the current strategy |
| So the momentum in that segment is really good |
| Excluding certain items, we anticipate operating profit to increase by approximately 8% to 11% year-over-year above the long-term target range |
| And I'm pleased to see our efforts being recognized |
| Obviously, the developments and advancements in that field have come on fast and when you think about a business that operates at our kind of scale, we're very excited about the opportunities we see there |
| pharmaceutical, we remain confident in our long-term target of 5% to 7% growth |
| I'm proud of what we've achieved as a team and I'm truly grateful to the McKesson employees for upholding our culture, values, and delivering for all of our stakeholders, our patients, our customers, our partners, our shareholders, and importantly, each other |
| Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good performance in our distribution businesses |
| pharmaceutical, adjusted operating profit grew 6%, reflecting broad-based momentum within the segment |
| Wrapping up fiscal 2024 guidance, as a result of solid performance in the third quarter of fiscal 2024 |
| First thing I would say is, I'm really pleased over the last several years, we have been very disciplined in making sure that we made organic investment or reinvestment back into the business |
| Supported by sustainable momentum in the core distribution business and across our oncology platform |
| And we're certainly pleased with the momentum that we're seeing in the segment |
| During the third quarter, we saw solid volume increases across customer channels, which includes distribution to retail national accounts customers |
| So to just sort of sum up, it's just continued strong utilization in the marketplace in general, continued good growth of our customers and channels, and continued growth within our oncology business |
| Certain product categories, including specialty pharmaceuticals and GLP-1 medications, continue to grow at a faster pace and contribute as a tailwind to our revenue growth |
| As the leader in the alternate site market, we believe that the Medical-Surgical Solution segment is well positioned as care continues to move across the alternate site settings |
| They delivered another strong quarter |
| In the international segment, our Canadian business continues to perform well |
| We're really pleased with our U.S |
| So it's been a competitive but stable marketplace in the generic space, but the capabilities that we have on sourcing, the ability for us to drive lower cost and high availability of product and generate spread for our customers in a disciplined way that has proven to be a good formula for us over a long period of time |
| Our Medical-Surgical Solutions segment continues to be a leader across all the alternate sites of care |
| And we think that our customers are benefiting as well |
| Statement |
|---|
| The overall illnesses and dynamics, including vaccinations and testing, continued to be an operating profit headwind in the quarter when compared to the prior year |
| However, when compared to the prior year, patient visit volumes in the medical segment remain a headwind to this quarter's performance |
| Finally, in the International segment, we anticipate revenues to decline by 29% to 33%, and operating profit to decline by 21% to 26%, reflecting divestitures within McKesson's European business that closed during fiscal 2023 |
| Third quarter operating profit decreased 9% to $1.3 billion |
| These medications are lower margin and represent a headwind to year-over-year operating profit growth |
| Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, storage, and distribution of ancillary supplies for the U.S |
| And as I mentioned, they have been an operating profit headwind year-over-year |
| Revenues in the third quarter were $3.6 billion, a decrease of 18% year-over-year, driven by divestitures within McKesson's European business, partially offset by higher pharmaceutical distribution volumes in Canada |
| In our fiscal third quarter, commercial COVID-19 vaccine distribution peaked in October, then declined significantly in November and December |
| We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year |
| Operating profit was $105 million, a decrease of 27%, driven by divestitures within McKesson's European business |
| As a reminder, we anticipate the growth from GLP-1 medications to slow in our fiscal fourth quarter, reflecting the inflection in volumes for these medications in the fourth quarter of fiscal 2023 |
| Each year, our teams come together to tackle the challenge of these significant volume increases |
| government's COVID-19 vaccine program and a softer illness season as compared to fiscal 2023 |
| Year-over-year results were also impacted by anticipated lower contributions from U.S |
| Third quarter free cash flow was impacted by the Right-Aid bankruptcy in October, and its associated $725 million provision for bad debts |
| We anticipate revenues to be approximately flat to 4% growth, and operating profit to decrease 11% to 15% |
| This year we do have commercial COVID vaccines that peaked in October and then really fell off |
| And then on the repo activity as well, slightly lower outlook here, three to three and a half billion versus prior 3.5 |
| Wrapping up our segment review, corporate expenses were $147 million in the quarter, which included losses of $8 million, or $0.05 per share, related to equity investments within the McKesson Ventures portfolio |
Please consider a small donation if you think this website provides you with relevant information